Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial to Evaluate Safety and Tolerability of BSI-045B mAb Injection in Healthy Adult Subjects and Patients With Atopic Dermatitis

NCT05114889 is registered in ClinicalTrials.gov with Biosion, Inc. as lead sponsor.

NCT NCT05114889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05114889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial to Evaluate Safety and Tolerability of BSI-045B mAb Injection in Healthy Adult Subjects and Patients With Atopic Dermatitis
Lead sponsor
Biosion, Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 25, 2021
Completion date
February 15, 2023
Enrollment
54 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis